Azam Erfanifar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Azam Erfanifar has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Hossein Toreyhi
Gastroenterology and Liver Diseases Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 shared publications - Muhanna Kazempour
Department of Rheumatology, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 shared publications - Pardis Jolfaei
Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 shared publications - Seyed Hadi Mirhashemi
Department of General Surgery, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 shared publications - Zahra Davoudi
Department of Internal Medicine, Loghman Hakim Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 shared publications - Ali Jahanian
Department of Pharmacology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
1 shared publication
Latest Publications
- Open Access
- 30 April 2026
- Published by Brieflands in Archives of Clinical Infectious Diseases
- Vol. 21 (2) , e173083
Behçet's Disease Manifesting as Panhypopituitarism Due to a Compressive Aspergillus Granuloma Adjacent to the Pituitary Gland: A Case Report
Introduction: Behçet's disease (BD) is a chronic, relapsing, multisystem inflammatory disorder of unknown etiology, characterized by mucocutaneous, ocular, neurologic, vascular, and gastrointestinal manifestations. Endocrine involvement, particularly hypothalamic-pituitary axis dysfunction, is uncommon and is often associated with neuro-Behçet syndrome or opportunistic infections in immunocompromised patients. Case Presentation: We report a rare case of a 51-year-old man with a 20-year history of BD and poorly controlled type 2 diabetes mellitus who presented with nausea, anorexia, abdominal pain, weight loss, and progressive blurred vision. He had been treated with prednisolone and azathioprine for BD and with insulin for diabetes. Laboratory findings showed hyperglycemia, elevated inflammatory markers, and adrenal insufficiency. Brain imaging revealed a heterogeneous sellar mass measuring 41 × 24 × 37 mm with hemorrhagic components and extension into the sphenoid sinus and nasopharynx, mimicking a pituitary macroadenoma with apoplexy. Transsphenoidal surgery evacuated a fungal granulomatous lesion that was positive for Aspergillus species by polymerase chain reaction and histopathology. Postoperative evaluation confirmed panhypopituitarism, prompting hormone replacement therapy with prednisolone, levothyroxine, and testosterone and antifungal treatment with initial amphotericin B followed by voriconazole. The patient's symptoms improved, inflammatory markers decreased by discharge, and his condition remained stable at the 2-month follow-up. Conclusions: This case highlights the need to consider fungal infections, such as aspergillosis, in the differential diagnosis of sellar masses in patients with BD, diabetes, or iatrogenic immunosuppression. Prompt surgical intervention, antifungal therapy, and endocrine management are critical for optimizing outcomes.
- 30 April 2026
- Published by Brieflands in Archives of Clinical Infectious Diseases
- Vol. 21 (2) , e173083
Open AccessBehçet's Disease Manifesting as Panhypopituitarism Due to a Compressive Aspergillus Granuloma Adjacent to the Pituitary Gland: A Case Report
Introduction: Behçet's disease (BD) is a chronic, relapsing, multisystem inflammatory disorder of unknown etiology, characterized by mucocutaneous, ocular, neurologic, vascular, and gastrointestinal manifestations. Endocrine involvement, particularly hypothalamic-pituitary axis dysfunction, is uncommon and is often associated with neuro-Behçet syndrome or opportunistic infections in immunocompromised patients. Case Presentation: We report a rare case of a 51-year-old man with a 20-year history of BD and poorly controlled type 2 diabetes mellitus who presented with nausea, anorexia, abdominal pain, weight loss, and progressive blurred vision. He had been treated with prednisolone and azathioprine for BD and with insulin for diabetes. Laboratory findings showed hyperglycemia, elevated inflammatory markers, and adrenal insufficiency. Brain imaging revealed a heterogeneous sellar mass measuring 41 × 24 × 37 mm with hemorrhagic components and extension into the sphenoid sinus and nasopharynx, mimicking a pituitary macroadenoma with apoplexy. Transsphenoidal surgery evacuated a fungal granulomatous lesion that was positive for Aspergillus species by polymerase chain reaction and histopathology. Postoperative evaluation confirmed panhypopituitarism, prompting hormone replacement therapy with prednisolone, levothyroxine, and testosterone and antifungal treatment with initial amphotericin B followed by voriconazole. The patient's symptoms improved, inflammatory markers decreased by discharge, and his condition remained stable at the 2-month follow-up. Conclusions: This case highlights the need to consider fungal infections, such as aspergillosis, in the differential diagnosis of sellar masses in patients with BD, diabetes, or iatrogenic immunosuppression. Prompt surgical intervention, antifungal therapy, and endocrine management are critical for optimizing outcomes.
- Open Access
- 24 May 2025
- Published by Brieflands in International Cardiovascular Research Journal
- Vol. 19 (1)
Aspirin Plus Rivaroxaban vs Aspirin Alone: Improvement of Claudication, Limb Pain and Ankle-Brachial Index in Diabetic Peripheral Arterial Disease (PAD) Before Revascularization: A Clinical Randomized Trial
Background: Peripheral artery disease (PAD) is a condition characterized by the occlusion of non-cardiac, non-intracranial peripheral arteries, which may result in reduced blood flow or tissue damage. The PAD is a common complication of type 2 diabetes mellitus. Aspirin (ASA) is the most commonly used antiplatelet medication in chronic stable PAD patients, and other medications are being tested to improve the efficacy of ASA. Objectives: This study aims to compare the effects of ASA monotherapy versus ASA and rivaroxaban dual therapy in improving the signs and symptoms of PAD. Methods: This is an open-label randomized controlled trial. Sixty type 2 diabetic patients with symptomatic PAD of the lower limbs were randomly divided into two groups using a computer-generated randomization schedule prepared before the study. In group A, thirty patients received rivaroxaban 2.5 mg twice a day and ASA 100 mg daily, while in group B, thirty patients received ASA 100 mg daily (initiated or continued at randomization) for 12 weeks. Intermittent claudication (IC), limb pain at rest/overnight, and Ankle-Brachial Index (ABI) were evaluated in patients before and after medication. The Wilcoxon test was used to compare values before and after treatment in each group, and the chi-square and Fisher Exact test were used to compare between groups. A P-value less than 0.05 was considered statistically significant. Results: Thirty patients were enrolled in each group and had similar baseline characteristics, with no significant differences in age, sex, smoking condition, and BMI (P-values of 0.87, 0.302, 0.95, and 0.448, respectively). After treatment, group A had lower rates of severe IC (33.3% vs 66.7%; P = 0.011), lower rates of rest pain (33.3% vs 70.0%; P = 0.009), and no cases of severe ABI (0.0% vs 23.3%; P = 0.001) compared to group B. Additionally, in group A, IC was completely resolved in one patient, and ABI was normalized in six patients after treatment. There was no incidence of bleeding and/or major adverse limb events. Conclusions: Our findings suggest that the combination of rivaroxaban and ASA is more potent than ASA alone for the treatment of PAD features, including IC, limb pain at rest/overnight, and ABI before revascularization therapy.
- 24 May 2025
- Published by Brieflands in International Cardiovascular Research Journal
- Vol. 19 (1)
Open AccessAspirin Plus Rivaroxaban vs Aspirin Alone: Improvement of Claudication, Limb Pain and Ankle-Brachial Index in Diabetic Peripheral Arterial Disease (PAD) Before Revascularization: A Clinical Randomized Trial
Background: Peripheral artery disease (PAD) is a condition characterized by the occlusion of non-cardiac, non-intracranial peripheral arteries, which may result in reduced blood flow or tissue damage. The PAD is a common complication of type 2 diabetes mellitus. Aspirin (ASA) is the most commonly used antiplatelet medication in chronic stable PAD patients, and other medications are being tested to improve the efficacy of ASA. Objectives: This study aims to compare the effects of ASA monotherapy versus ASA and rivaroxaban dual therapy in improving the signs and symptoms of PAD. Methods: This is an open-label randomized controlled trial. Sixty type 2 diabetic patients with symptomatic PAD of the lower limbs were randomly divided into two groups using a computer-generated randomization schedule prepared before the study. In group A, thirty patients received rivaroxaban 2.5 mg twice a day and ASA 100 mg daily, while in group B, thirty patients received ASA 100 mg daily (initiated or continued at randomization) for 12 weeks. Intermittent claudication (IC), limb pain at rest/overnight, and Ankle-Brachial Index (ABI) were evaluated in patients before and after medication. The Wilcoxon test was used to compare values before and after treatment in each group, and the chi-square and Fisher Exact test were used to compare between groups. A P-value less than 0.05 was considered statistically significant. Results: Thirty patients were enrolled in each group and had similar baseline characteristics, with no significant differences in age, sex, smoking condition, and BMI (P-values of 0.87, 0.302, 0.95, and 0.448, respectively). After treatment, group A had lower rates of severe IC (33.3% vs 66.7%; P = 0.011), lower rates of rest pain (33.3% vs 70.0%; P = 0.009), and no cases of severe ABI (0.0% vs 23.3%; P = 0.001) compared to group B. Additionally, in group A, IC was completely resolved in one patient, and ABI was normalized in six patients after treatment. There was no incidence of bleeding and/or major adverse limb events. Conclusions: Our findings suggest that the combination of rivaroxaban and ASA is more potent than ASA alone for the treatment of PAD features, including IC, limb pain at rest/overnight, and ABI before revascularization therapy.
- 3 March 2025
- Published by Springer Nature in Obesity Surgery
- Vol. 35 (4) , 1307-1315
Impact of BMI Reduction After Sleeve Surgery on ESR and CRP Levels in Patients with Obesity
Background Obesity is commonly linked with a pro-inflammatory condition, marked by elevated levels of inflammatory biomarkers such as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR). Sleeve gastrectomy, a widely utilized bariatric procedure, aims to achieve substantial weight loss and enhance metabolic function. This study aims to examine the impact of body mass index (BMI) reduction following sleeve gastrectomy on the levels of inflammatory markers CRP and ESR in obese individuals. Methods A prospective observational study was carried out on patients with obesity who underwent sleeve gastrectomy between 2020 and 2022 at Luqman Hakim Medical Education Center. CRP and ESR levels were recorded preoperatively and then at 6- and 12-month post-surgery. Simple regression analysis was employed to evaluate the correlation between BMI reduction and changes in CRP and ESR levels over time. Results A significant reduction in BMI, CRP, and ESR levels was observed at both 6- and 12-month post-surgery. However, regression analysis indicated that BMI reduction did not significantly predict changes in ESR (B = 0.209, p = 0.262) or CRP (B = 0.274, p = 0.079) at the 6-month and 12-month follow-ups (CRP: B = 0.123, p = 0.138; ESR: B = 0.122, p = 0.453). Conclusions While sleeve gastrectomy significantly reduces BMI and inflammatory markers such as CRP and ESR in patients with obesity, the direct association between BMI reduction and these markers was not statistically significant. Further studies are warranted to elucidate the underlying mechanisms and identify other potential predictors of inflammatory marker reduction post-surgery.
- 3 March 2025
- Published by Springer Nature in Obesity Surgery
- Vol. 35 (4) , 1307-1315
Impact of BMI Reduction After Sleeve Surgery on ESR and CRP Levels in Patients with Obesity
Background Obesity is commonly linked with a pro-inflammatory condition, marked by elevated levels of inflammatory biomarkers such as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR). Sleeve gastrectomy, a widely utilized bariatric procedure, aims to achieve substantial weight loss and enhance metabolic function. This study aims to examine the impact of body mass index (BMI) reduction following sleeve gastrectomy on the levels of inflammatory markers CRP and ESR in obese individuals. Methods A prospective observational study was carried out on patients with obesity who underwent sleeve gastrectomy between 2020 and 2022 at Luqman Hakim Medical Education Center. CRP and ESR levels were recorded preoperatively and then at 6- and 12-month post-surgery. Simple regression analysis was employed to evaluate the correlation between BMI reduction and changes in CRP and ESR levels over time. Results A significant reduction in BMI, CRP, and ESR levels was observed at both 6- and 12-month post-surgery. However, regression analysis indicated that BMI reduction did not significantly predict changes in ESR (B = 0.209, p = 0.262) or CRP (B = 0.274, p = 0.079) at the 6-month and 12-month follow-ups (CRP: B = 0.123, p = 0.138; ESR: B = 0.122, p = 0.453). Conclusions While sleeve gastrectomy significantly reduces BMI and inflammatory markers such as CRP and ESR in patients with obesity, the direct association between BMI reduction and these markers was not statistically significant. Further studies are warranted to elucidate the underlying mechanisms and identify other potential predictors of inflammatory marker reduction post-surgery.
- 17 December 2024
- Published by Springer Nature in Obesity Surgery
- Vol. 35 (1) , 189-197
Sleeve Gastrectomy and Its Impact on Insulin Resistance and Metabolic Health: A Cohort Study
Background Obesity is a prevalent metabolic disorder that significantly contributes to insulin resistance (IR), type 2 diabetes (T2DM), and metabolic syndrome. Sleeve gastrectomy has emerged as an effective surgical intervention for obesity, with potential benefits on metabolic health. This study investigates the impact of sleeve gastrectomy on serum insulin levels, IR (HOMA-IR), inflammatory markers, C-peptide, kidney function, and various biochemical parameters in diabetic and non-diabetic patients. Methods A prospective cohort study was conducted, involving 199 patients over 18 years old who were candidates for sleeve gastrectomy at Luqman Hakim Hospital from 2021 to 2022. Data were collected using standardized questionnaires and anthropometric measurements, and biochemical assessments were performed before surgery and 6 months postoperatively. Statistical analyses included descriptive statistics, t-tests, Mann–Whitney tests, and repeated measures analysis of variances (ANOVA). Results The study included 199 patients (84.4% female) with a mean (± standard deviation (SD)) age of 39.79 ± 11.30 years. Significant reductions were observed in weight, BMI, and abdominal circumference across all patient groups. Diabetic patients showed marked improvements in fasting blood sugar, 2-h postprandial blood sugar, and glycosylated hemoglobin levels. Insulin resistance decreased significantly, as did serum insulin and C-peptide levels. Improvements in lipid profiles and inflammatory markers were also noted. Insulin use post-surgery showed a significant inverse relationship with glycemic control improvement. Conclusions Sleeve gastrectomy is a safe and effective procedure for obese patients, significantly improving insulin resistance and various obesity-associated diseases within 6 months post-surgery.
- 17 December 2024
- Published by Springer Nature in Obesity Surgery
- Vol. 35 (1) , 189-197
Sleeve Gastrectomy and Its Impact on Insulin Resistance and Metabolic Health: A Cohort Study
Background Obesity is a prevalent metabolic disorder that significantly contributes to insulin resistance (IR), type 2 diabetes (T2DM), and metabolic syndrome. Sleeve gastrectomy has emerged as an effective surgical intervention for obesity, with potential benefits on metabolic health. This study investigates the impact of sleeve gastrectomy on serum insulin levels, IR (HOMA-IR), inflammatory markers, C-peptide, kidney function, and various biochemical parameters in diabetic and non-diabetic patients. Methods A prospective cohort study was conducted, involving 199 patients over 18 years old who were candidates for sleeve gastrectomy at Luqman Hakim Hospital from 2021 to 2022. Data were collected using standardized questionnaires and anthropometric measurements, and biochemical assessments were performed before surgery and 6 months postoperatively. Statistical analyses included descriptive statistics, t-tests, Mann–Whitney tests, and repeated measures analysis of variances (ANOVA). Results The study included 199 patients (84.4% female) with a mean (± standard deviation (SD)) age of 39.79 ± 11.30 years. Significant reductions were observed in weight, BMI, and abdominal circumference across all patient groups. Diabetic patients showed marked improvements in fasting blood sugar, 2-h postprandial blood sugar, and glycosylated hemoglobin levels. Insulin resistance decreased significantly, as did serum insulin and C-peptide levels. Improvements in lipid profiles and inflammatory markers were also noted. Insulin use post-surgery showed a significant inverse relationship with glycemic control improvement. Conclusions Sleeve gastrectomy is a safe and effective procedure for obese patients, significantly improving insulin resistance and various obesity-associated diseases within 6 months post-surgery.
- 1 January 2019
- Published by Elsevier in Diabetes & Metabolic Syndrome: Clinical Research & Reviews
- Vol. 13 (1) , 201-205
Incidence of obesity, overweight and hypertension in children and adolescents in Ahvaz southwest of IRAN: Five-years study
- 1 January 2019
- Published by Elsevier in Diabetes & Metabolic Syndrome: Clinical Research & Reviews
- Vol. 13 (1) , 201-205
Incidence of obesity, overweight and hypertension in children and adolescents in Ahvaz southwest of IRAN: Five-years study